Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.47 |
| ▸ | PIM1 | P11309 | 9/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CDK9 | P50750 | 2/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.42 |
| ▸ | FYN | P06241 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3865962 | 0.94 | MKNK1 (0.47) | MKNK1PIM1DYRK3CCNT1CCNA2 | |
| SCHEMBL3869751 | 0.90 | PIM1 (0.54) | PIM1DYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL3868540 | 0.90 | PIM1 (0.47) | MKNK1PIM1DYRK3CCNT1CCNA2 | |
| SCHEMBL3866313 | 0.88 | DYRK3 (0.45) | MKNK1PIM1DYRK3CCNT1CCNA2 | |
| SCHEMBL3866139 | 0.88 | PIM1 (0.50) | MKNK1PIM1DYRK3CCNT1CCNA2 | |
| SCHEMBL4046562 | 0.88 | FYN (0.53) | PIM1FYN | |
| SCHEMBL3867064 | 0.88 | MKNK1 (0.42) | MKNK1PIM1DYRK3CCNT1CCNA2 | |
| SCHEMBL3865829 | 0.86 | PIM1 (0.59) | PIM1DYRK1A | |
| SCHEMBL4052174 | 0.86 | AKT1 (0.44) | MKNK1PIM1DYRK3CCNT1CCNA2 | |
| SCHEMBL3868645 | 0.86 | MKNK1 (0.42) | MKNK1PIM1DYRK3CCNT1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653076-B2 | Oxo-substituted imidazo[1,2B]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | CDK2, CDK1, MAP4K2 | MKNK1 299/4885PIM1 712/4885DYRK3 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.